José A. Salas

Also affiliated with IQVIA (United Kingdom), Instituto Nacional de Silicosis, Instituto de Investigación Sanitaria del Principado de Asturias

MedicineChemistryBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial”.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Infectious Diseases(2022)10.1016/s1473-3099(22)00506-0

N/A

2.0DataRank · unranked

89 citations

An Vandebosch, Jerald Sadoff, Mathieu Le Gars, Carla Truyers, D. Lowson +95 more